Journal article
British Society for Echocardiography and British Cardio-Oncology Society guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab
R Dobson, AK Ghosh, B Ky, T Marwick, M Stout, A Harkness, R Steeds, S Robinson, D Oxborough, D Adlam, S Stanway, B Rana, T Ingram, L Ring, S Rosen, C Plummer, C Manisty, M Harbinson, V Sharma, K Pearce Show all
Echo Research and Practice | Published : 2021
DOI: 10.1530/ERP-21-0001
Abstract
The subspecialty of cardio-oncology aims to reduce cardiovascular morbidity and mortality in patients with cancer or following cancer treatment. Cancer therapy can lead to a variety of cardiovascular complications, including left ventricular systolic dysfunction, pericardial disease, and valvular heart disease. Echocardiography is a key diagnostic imaging tool in the diagnosis and surveillance for many of these complications. The baseline assessment and subsequent surveillance of patients undergoing treatment with anthracyclines and/or human epidermal growth factor (EGF) receptor (HER) 2-positive targeted treatment (e.g. trastuzumab and pertuzumab) form a significant proportion of cardio-onc..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
This work was supported by National Institutes of Health grant R01 HL 118018 (Dr Ky).